[Statins and cerebrovascular disease: new perspectives in stroke prevention].
BACKGROUND
The role played by statins in the prevention of strokes has been subject to controversy for a long time, especially because no clear correlation between levels of cholesterol in serum and strokes has yet been established. Nevertheless, a number of randomised trials with statins and several meta-analyses that were carried out later have proved that statins lower the incidence of all kinds of strokes, with a 21% reduction in the relative risk. It has also been shown that this effect is essentially due to the degree to which LDL cholesterol (cholesterol linked to low-density lipoproteins) is reduced, which has a lowering effect on lipid levels. It has also been shown that statins have others beneficial effects apart from reducing cholesterol levels and that these may be independent of the subject's basal lipid levels. We are referring to the so-called pleiotropic effects, which include stabilisation of the atherosclerotic plaque, an antiinflammatory effect, an antithrombotic effect and enhanced vasomotor reactivity.


CONCLUSIONS
The recent appearance of the results of the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) study and the guidelines published by the American Heart Association and the Spanish Neurology Society, which grant statins a leading role in stroke prevention, both open up new horizons for the use of statins in cerebrovascular pathologies.
Castilla-Guerra
L
L
Hospital de la Merced, Osuna, España. castillafernandez@hotmail.com
Fernández-Moreno
M C
MC
López-Chozas
J M
JM
Jiménez-Hernández
M D
MD
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000517:prevention & control; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D008078:Cholesterol, LDL / Q000097:blood; D004334:Drug Administration Schedule; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy / Q000517:prevention & control; D015337:Multicenter Studies as Topic; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D020521:Stroke / Q000517:prevention & control*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D008078:Cholesterol, LDL; D005343:Fibrinolytic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors